Stanley Riddell
Medical Oncology · Seattle, WANPI 1215147947
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $21,210 of the $21,304 with a category attached, or 99.6%. Bristol Myers Squibb accounts for 88.1% of it on its own, with 2 other manufacturers making up the rest.
Across 5 payments — averaging $4260.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$19K
- AstraZeneca$2K
- GSK$70
Across 5 payments — averaging $669,911 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$3.3M
What the payments were for
- Consulting fees$21,210100%
- Food & beverage$940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 3 | $18,774 |
| AstraZeneca | 1 | $2,460 |
| GSK | 1 | $70 |
How this compares
$21,304 in reported general payments places this provider in the 75th percentile of 162 medical oncology providers in Washington.
Other medical oncology in Seattle
- Bart ScottSeattle$1.3M
- Petros GrivasSeattle$628K
- Vijayakrishna GadiSeattle$573K
- Evan YuSeattle$296K
- Siddhartha DevarakondaSeattle$215K
- David MaloneySeattle$150K
- Gary LymanSeattle$130K
- Rafic FarahSeattle$114K
- Laura ChowSeattle$114K
- Shailender BhatiaSeattle$107K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.